Clin2
NCT06215950Possibly a fitRecruiting

CAR-T cell therapy for advanced gynecologic cancer with CD70 protein

Ovarian CancerCervix CancerMetastatic CancerAdvanced CancerGynecologic Cancer

Treatments studied

Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.

This trial tests a new treatment called CAR-T cells that target a protein called CD70 found on some gynecologic cancer cells. It is for people whose cancer has advanced or spread and has not responded to or stopped responding to standard treatments.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
36 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You have advanced or metastatic gynecologic cancer that tested positive for a protein called CD70.
  • Your cancer has progressed or you cannot tolerate standard treatments like surgery, chemotherapy, or radiation.
  • You have at least one tumor that can be measured on a CT scan.
  • You are generally well enough to be up and about for at least half the day (ECOG score 0-2).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05518253Recruiting· Phase 1
CAR-T treatment for CD70-positive advanced solid tumors

This trial tests a lab-made immune therapy (CAR-T) that targets a protein called CD70 found on some advanced cancers. It’s designed for people whose solid tumors have spread and no standard treatments have worked or weren’t tolerated.

Hangzhou, Zhejiang
NCT07181720Recruiting· Phase 1
CD70-targeted CAR-T therapy for advanced solid tumors

This trial tests a new treatment called CAR-T that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments.

Hefei, Anhui
NCT06010875Recruiting· Phase 1
CD70-targeted CAR-T cell therapy for advanced solid tumors

This trial tests a new treatment using your own immune cells (CAR-T cells) designed to attack cancer cells that have a protein called CD70. It is for people with advanced solid tumors that have not responded to standard treatments.

Nanchang, Jiangxi
NCT06383507Not yet recruiting· Phase 1
CAR-T cell therapy targeting CD70 for advanced solid tumors

This trial tests a new type of immune cell therapy (CAR-T) that targets a protein called CD70 found on some solid tumors. It is for people whose cancer has not responded to other treatments and whose tumor tests positive for CD70. The goal is to see if this treatment can help shrink tumors.

NCT07067255Recruiting· Phase 1/Phase 2
Sequential CAR-T cells for advanced ovarian cancer with CD146 and GPC3

This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack ovarian cancer cells that have two specific markers (CD146 and GPC3). It is for people with advanced ovarian cancer who have already tried standard treatments like platinum-based chemotherapy and need new options.

Beijing, Beijing Municipality
NCT06305299Recruiting· Phase 1
CAR-T cell therapy for ovarian cancer

This trial tests a new treatment called CAR-T cells that target a protein called B7H3 found on cancer cells. It is for people with a specific type of ovarian, peritoneal, or fallopian tube cancer that has not responded well to platinum chemotherapy or has come back quickly.

Chapel Hill, North Carolina

Hear when a new Ovarian cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.